Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54.7M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
40.3M
-
Shares change
-
-1.65M
-
Total reported value, excl. options
-
$372M
-
Value change
-
-$19.2M
-
Put/Call ratio
-
0.29
-
Number of buys
-
53
-
Number of sells
-
-41
-
Price
-
$9.23
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q4 2022
119 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2022.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.3M shares
of 54.7M outstanding shares and own 73.62% of the company stock.
Largest 10 shareholders include Skorpios Trust (14.4M shares), RTW INVESTMENTS, LP (3.87M shares), FMR LLC (3.03M shares), MORGAN STANLEY (2.45M shares), BlackRock Inc. (1.83M shares), VANGUARD GROUP INC (1.6M shares), BAKER BROS. ADVISORS LP (1.11M shares), Cormorant Asset Management, LP (1.09M shares), Octagon Capital Advisors LP (763K shares), and COWEN AND COMPANY, LLC (748K shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.